Drug Evaluation

Erdafitinib in locally advanced/metastatic urothelial carcinoma with certain FGFR genetic alterations

https://orcid.org/0000-0003-2452-8099

Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, 20133, Italy

Search for more papers by this author

Marta Pirovano

Department of Nephrology & Dialysis, ASST Fatebenefratelli-Sacco, Milan, 20157, Italy

Department of Biomedical & Clinical Sciences ‘L. Sacco,’ University of Milan, Milan, 20122, Italy

Search for more papers by this author

Patrizia Giannatempo

*Author for correspondence: Tel.: +39 022 390 2402;

E-mail Address: patrizia.giannatempo@istitutotumori.mi.it

Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, 20133, Italy

Search for more papers by this author

Laura Cosmai

Department of Nephrology & Dialysis, ASST Fatebenefratelli-Sacco, Milan, 20157, Italy

Search for more papers by this author

Published Online:7 Apr 2022https://doi.org/10.2217/fon-2021-1151

View article

Abstract

FGFR inhibitors represent a new and promising therapeutic approach to urothelial cancer (UC). Erdafitinib (Balversa^©) was the first FGFR inhibitor approved for the treatment of metastatic UC, showing proper pharmacological activity and a consistent safety profile in a population with limited or no therapeutic alternatives. While results from comparative phase II and III trials are needed to assess the efficacy of erdafitinib in different clinical settings, there are still questions unsolved regarding a typical class effect of FGFR inhibitors, hyperphosporemia. In this review, the authors focus on the state-of-art administration of erdatifinib in advanced UC, pointing out the more recent evidence, pitfalls and possible future research. Insight on the management of hyperphosporemia in patients undergoing treatment with FGFR inhibitors is also provided.

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1. Sung H, Ferlay J, Siegel RL et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71(3), 209–249 (2021).
MedlineGoogle Scholar
2. Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder cancer incidence and mortality: a global overview and recent trends. Eur. Urol. 71(1), 96–108 (2017).
MedlineGoogle Scholar
3. Cumberbatch MGK, Jubber I, Black PC et al. Epidemiology of bladder cancer: a systematic review and contemporary update of risk factors in 2018. Eur. Urol. 74(6), 784–795 (2018).
MedlineGoogle Scholar
4. Nadal R, Bellmunt J. Management of metastatic bladder cancer. Cancer Treat. Rev. 76, 10–21 (2019).
Medline CASGoogle Scholar
5. von der Maase H, Hansen SW, Roberts JT et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. JCO 18(17), 3068–3077 (2000).
MedlineGoogle Scholar
6. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer v1.22 (2022). www.nccn.org/professionals/physician_gls/pdf/bladder.pdf
Google Scholar
7. Kaufman D, Raghavan D, Carducci M et al. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. JCO 18(9), 1921–1927 (2000).
Medline CASGoogle Scholar
8. Necchi A, Pond GR, Raggi D et al. Efficacy and safety of gemcitabine plus either taxane or carboplatin in the first-line setting of metastatic urothelial carcinoma: a systematic review and meta-analysis. Clin. Genitour. Cancer 15(1), 23–30.e2 (2017).
MedlineGoogle Scholar
9. Fradet Y, Bellmunt J, Vaughn DJ et al. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. Ann. Oncol. 30(6), 970–976 (2019).
Medline CASGoogle Scholar
10. Rosenberg JE, Hoffman-Censits J, Powles T et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387(10031), 1909–1920 (2016).
Medline CASGoogle Scholar
11. Powles T, van der Heijden MS, Castellano D et al. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 21(12), 1574–1588 (2020).
Medline CASGoogle Scholar
12. Sharma P, Siefker-Radtke A, de Braud F et al. Nivolumab alone and with ipilimumab in previously treated metastatic urothelial carcinoma: CheckMate 032 nivolumab 1 mg/kg plus ipilimumab 3 mg/kg expansion cohort results. JCO 37(19), 1608–1616 (2019).
Medline CASGoogle Scholar
13. Balar AV, Galsky MD, Rosenberg JE et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 389(10064), 67–76 (2017).
Medline CASGoogle Scholar
14. Balar AV, Castellano D, O'Donnell PH et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 18(11), 1483–1492 (2017).
Medline CASGoogle Scholar
15. Powles T, Rosenberg JE, Sonpavde GP et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N. Engl. J. Med. 384(12), 1125–1135 (2021).
Medline CASGoogle Scholar
16. Roskoski R. The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder. Pharmacol. Res. 151, 104567 (2020).
Medline CASGoogle Scholar
17. The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507(7492), 315–322 (2014).
MedlineGoogle Scholar
18. Robertson AG, Kim J, Al-Ahmadie H et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell 171(3), 540–556.e25 (2017).
Medline CASGoogle Scholar
19. Nassar AH, Umeton R, Kim J et al. Mutational analysis of 472 urothelial carcinoma across grades and anatomic sites. Clin. Cancer Res. 25(8), 2458–2470 (2019).
MedlineGoogle Scholar
20. Babina IS, Turner NC. Advances and challenges in targeting FGFR signaling in cancer. Nat. Rev. Cancer 17(5), 318–332 (2017).
Medline CASGoogle Scholar
21. Morales-Barrera R, Suárez C, de Castro AM et al. Targeting fibroblast growth factor receptors and immune checkpoint inhibitors for the treatment of advanced bladder cancer: new direction and new hope. Cancer Treat. Rev. 50, 208–216 (2016).
Medline CASGoogle Scholar
22. Milowsky MI, Dittrich C, Durán I et al. Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma. Eur. J. Cancer 50(18), 3145–3152 (2014).
Medline CASGoogle Scholar
23. Mazzola CR, Siddiqui KM, Billia M, Chin J. Dovitinib: rationale, preclinical and early clinical data in urothelial carcinoma of the bladder. Exp. Opin. Investig. Drugs 23(11), 1553–1562 (2014).
Medline CASGoogle Scholar
24. Hoy SM. Pemigatinib: first approval. Drugs 80(9), 923–929 (2020).
MedlineGoogle Scholar
25. Pal SK, Rosenberg JE, Hoffman-Censits JH et al. Efficacy of BGJ398, a fibroblast growth factor receptor 1–3 inhibitor, in patients with previously treated advanced urothelial carcinoma with FGFR3 alterations. Cancer Discov. 8(7), 812–821 (2018).
Medline CASGoogle Scholar
26. Siefker-Radtke AO, Currie G, Abella E et al. FIERCE-22: clinical activity of vofatamab (V) a FGFR3 selective inhibitor in combination with pembrolizumab (P) in WT metastatic urothelial carcinoma, preliminary analysis. JCO 37(Suppl. 15), 4511–4511 (2019).
Google Scholar
27. Casadei C, Dizman N, Schepisi G et al. Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors. Ther. Adv. Med. Oncol. 11, 175883591989028 (2019).
Google Scholar
28. Scholtes MP, Alberts AR, Iflé IG, Verhagen PCMS, van der Veldt AAM, Zuiverloon TCM. Biomarker-oriented therapy in bladder and renal cancer. IJMS 22(6), 2832 (2021).
Medline CASGoogle Scholar
29. Marandino L, Raggi D, Giannatempo P, Farè E, Necchi A. Erdafitinib for the treatment of urothelial cancer. Exp. Rev. Anticancer Ther. 19(10), 835–846 (2019). •• A comprehensive review of current knowledge about erdafitinib an its administration in urothelial cancer.
MedlineGoogle Scholar
30. Perera TPS, Jovcheva E, Mevellec L et al. Discovery and pharmacological characterization of JNJ-42756493 (erdafitinib), a functionally selective small-molecule FGFR family inhibitor. Mol. Cancer Ther. 16(6), 1010–1020 (2017). • The results of this study provide a strong rationale for the clinical investigation of JNJ-42756493 in patients with tumors harboring FGFR pathway alterations.
Medline CASGoogle Scholar
31. Roskoski R. Properties of FDA-approved small molecule protein kinase inhibitors: a 2020 update. Pharmacol. Res. 152, 104609 (2020).
Medline CASGoogle Scholar
32. Bahleda R, Italiano A, Hierro C et al. Multicenter phase I study of erdafitinib (JNJ-42756493), oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced or refractory solid tumors. Clin. Cancer Res. 25(16), 4888–4897 (2019). • Erdafitinib showed encouraging responses in urothelial carcinoma and cholangiocarcinoma in this phase I clinical trial.
Medline CASGoogle Scholar
33. Li LY, Guo Y, Gonzalez M, Ouellet D. Effect of plasma protein binding on the pharmacokinetics of erdafitinib: results of an integrated cross-study analysis. J. Clin. Pharmacol. 60(3), 391–399 (2020).
Medline CASGoogle Scholar
34. Dosne A, Valade E, Stuyckens K, Li LY, Ouellet D, Perez-Ruixo JJ. Population pharmacokinetics of total and free erdafitinib in adult healthy volunteers and cancer patients: analysis of phase 1 and phase 2 studies. J. Clin. Pharmacol. 60(4), 515–527 (2020).
Medline CASGoogle Scholar
35. Nauseef JT, Villamar DM, Lebenthal J, Vlachostergios PJ, Tagawa ST. An evaluation of the efficacy and safety of Erdafitinib for the treatment of bladder cancer. Exp. Opin. Pharmacother. 21(8), 863–870 (2020).
Medline CASGoogle Scholar
36. Tabernero J, Bahleda R, Dienstmann R et al. Phase I dose-escalation study of JNJ-42756493, an oral pan–fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors. JCO 33(30), 3401–3408 (2015). • Erdafitinib demonstrated pharmacodynamic biomarker activity and had a manageable safety profile in this clinical trial.
Medline CASGoogle Scholar
37. FDA.gov. FDA approves first targeted therapy for metastatic bladder cancer (2019). www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-Erdafitinib-metastatic-urothelial-carcinoma
Google Scholar
38. Loriot Y, Necchi A, Park SH et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N. Engl. J. Med. 381(4), 338–348 (2019). •• In this study, the use of erdafitinib was associated with objective tumor response in 40% of previously treated patients with advanced urothelial carcinoma with FGFR alterations.
Medline CASGoogle Scholar
39. Kommalapati A, Tella SH, Borad M, Javle M, Mahipal A. FGFR inhibitors in oncology: insight on the management of toxicities in clinical practice. Cancers 13(12), 2968 (2021).
Medline CASGoogle Scholar
40. Roubal K, Myint ZW, Kolesar JM. Erdafitinib: a novel therapy for FGFR-mutated urothelial cancer. Am. J. Health Syst. Pharm. 77(5), 346–351 (2020).
MedlineGoogle Scholar
41. Lu X, Hu MC. Klotho/FGF23 axis in chronic kidney disease and cardiovascular disease. Kidney Dis. 3(1), 15–23 (2017).
Google Scholar
42. Brauer A, Waheed S, Singh T, Maursetter L. Improvement in hyperphosphatemia using phosphate education and planning talks. J. Ren. Nutri. 29(2), 156–162 (2019).
MedlineGoogle Scholar
43. Joshi S, Potluri V, Shah S. Dietary management of hyperphosphatemia. Am. J. Kidney Dis. 72(1), 155–156 (2018).
MedlineGoogle Scholar
44. Moe SM, Zidehsarai MP, Chambers MA et al. Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease. CJASN 6(2), 257–264 (2011).
Medline CASGoogle Scholar
45. Ghimire S, Castelino RL, Lioufas NM, Peterson GM, Zaidi STR. Nonadherence to medication therapy in haemodialysis patients: a systematic review. PLoS ONE 10(12), e0144119 (2015).
MedlineGoogle Scholar
46. Navarro-González JF, Sánchez-Niño MD, Donate-Correa J et al. Effects of pentoxifylline on soluble klotho concentrations and renal tubular cell expression in diabetic kidney disease. Dia. Care 41(8), 1817–1820 (2018).
Medline CASGoogle Scholar
47. ClinicalTrials.gov. A Study of erdafitinib compared with vinflunine or docetaxel or pembrolizumab in participants with advanced urothelial cancer and selected fibroblast growth factor receptor (FGFR) gene aberrations (2022). https://clinicaltrials.gov/ct2/show/NCT03390504
Google Scholar
48. Moreno V, Loriot Y, Valderrama BP et al. Does escalation results from phase Ib/II Norse study of erdafitinib (ERDA) + PD-1 inhibitor JNJ-63723283 (cetrelimab [CET]) in patients (pts) with metastatic or locally advanced urothelial carcinoma (mUC) and selected fibroblast growth factor receptor (FGFR) gene alterations. JCO 38(Suppl. 6), 511–511 (2020).
Google Scholar
49. ClinicalTrials.gov. A study of erdafitinib in participants with metastatic or locally advanced urothelial cancer (2022). https://clinicaltrials.gov/ct2/show/NCT03473743
Google Scholar

Vol. 18, No. 19

Metrics

Downloaded 186 times

History

Received 10 September 2021

Accepted 9 March 2022

Published online 7 April 2022

Published in print June 2022

Information

Keywords

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

PDF download